Rate of natural disease progression in patients with chronic hepatitis C

Journal of Hepatology

Volumn 38, Issue 3, 2003, Pages 307-314

  Zarski, Jean Pierre ^a,b   Mc Hutchison, John ^c   Bronowicki, Jean Pierre ^d   Sturm, Nathalie ^a   Garcia Kennedy, Richard ^e   Hodaj, Enkelejda ^a   Truta, Brenda ^b   Wright, Teresa ^b   Gish, Robert ^e  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d CHU NANCY BRABOIS   (France)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Liver disease; Liver fibrosis

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 0037335210     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00387-2     Document Type: Article

References (29)

1. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999;31:17-24.
2. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-816.
3. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29:1596-1601.
4. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment. J Viral Hepat 2000;7:268-275.
5. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S-15S.
6. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
8. Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol 2000;14:211-228.
9. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001;34:730-739.
10. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
11. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
12. Marcellin PAR, Cazals-Hatem D, Boyer N, Martinot M, Vidaud D, Degott C. Prospective study of progression of fibrosis in untreated patients with mild chronic hepatitis C (abstract). Hepatology 2000;32(Suppl):380A.
13. Alberti ABS, Ferrari A, Benvegnu L, Pontisso P, Noventa F. Outcome of initially mild chronic hepatitis C (abstract). Hepatology 2001;34:225A.
14. Sobesky R, Mathurin P, Charlotte F, Moussali J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-386.
15. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-789.
16. Minuk GY. The influence of host factors on the natural history of chronic hepatitis C viral infections. J Viral Hepat 1999;6:271-276.
17. Wong V, Caronia S, Wight D, Palmer CR, Petrik J, Britton P, et al. Importance of age in chronic hepatitis C virus infection. J Viral Hepat 1997;4:255-264.
18. Khan MH, Thomas L, Byth K, Kench J, Weltman M, George J, et al. How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 1998;13:419-426.
19. Pessione F, Degos F, Marcellin P, Duchatelle V, Njadoum C, Martinot Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-1722.
20. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809.
21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
22. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211-215.
23. De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998;42:856-860.
24. Paradis V, Mathurin P, Laurent A, Charlotte F, Vidaud M, Poynard T, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996;49:998-1004.
25. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shothouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
26. Ratziu VDMM, Bonyhay L, Charlotte F, Opolon P, Poynard T. Impact of high serum glucose on liver fibrosis in chronic hepatitis C (abstract). J Hepatol 2001;34:163.
27. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
28. National Institutes of Health Consensus Development Conference. Panel statement: management of hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
29. Consensus Conference. Hepatitis C: screening and treatment. Gastroenterol Clin Biol 1997;21:S1-S216.